1
Edgar A Steck, Carl R Alving: Liposome carriers in chemotherapy of leishmaniasis. The United States of America represented by the Secretary of the Army, William C Gapcynski, Werten F W Bellamy, Sherman D Winters, January 29, 1980: US04186183 (94 worldwide citation)

An improved method is provided for the chemotherapy of leishmanial infections. The anti-leishmanial agent is encapsulated within liposomes and the liposome-encapsulated drug is injected into the body. Subject use of a liposome carrier has produced marked enhancement of the effectiveness and duration ...


2
Gregory M Glenn, Carl R Alving: Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response. The United States of America represented by the Secretary of the Army, Morgan Lewis & Bockius, September 28, 2004: US06797276 (60 worldwide citation)

A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a ystemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancemen ...


3
Andrew S Janoff, Mircea C Popescu, Carl R Alving, Michael W Fountain, Robert P Lenk, Marc J Ostro, Paul A Tremblay, Alan L Weiner: Drug preparations of reduced toxicity. The Liposome Company, Allen Bloom, Catherine L Kurtz, October 22, 1991: US05059591 (49 worldwide citation)

Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.


4
Mircea C Popescu, Alan L Weiner, Marie S Recine, Andrew S Janoff, Leonard Estis, Lynn D Keyes, Carl R Alving: Potentiation of immune responses with liposomal adjuvants. The Liposome Company, Kenneth B Rubin, Rosanne Goodman, July 18, 2000: US06090406 (40 worldwide citation)

A high integrity liposome comprising at least one stabile lipid and at least one peptide-like therapeutic agent associated with said liposome, adapted for parenteral administration to an animal, including a human, and method according to manufacture and use. Immunizing dosage forms comprising a lipo ...


5
Carl R Alving, Gregory M Glenn: Transdermal delivery system for antigen. The United States of America represented by the Secretary of the Army, Pillsbury Madison & Sutro, June 8, 1999: US05910306 (37 worldwide citation)

A transdermal liposome system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses liposomes to deliver a variety of antigens which can elicit an antigen-specific immune response (e.g., humoral and/or cellular effecto ...


6
Andrew S Janoff, Carl R Alving, Michael W Fountain, Robert P Lenk, Marc J Ostro, Mircea C Popescu, Paul A Tremblay, Alan L Weiner: Drug preparations of reduced toxicity. The Liposome Company, Allen Bloom, Thomas M Saunders, January 30, 1990: US04897384 (34 worldwide citation)

Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.


7
Mircea C Popescu, Alan L Weiner, Marie S Recine, Andrew S Janoff, Leonard Estis, Lynn D Keyes, Carl R Alving: Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use. The Liposome Company, Kenneth Rubin, Rosanne Goodman, June 29, 1999: US05916588 (32 worldwide citation)

A high integrity liposome comprising at least one stabile lipid and at least one peptide-like therapeutic agent associated with the liposome, adapted for parenteral administration to an animal, including a human, and method according to manufacture and use.


8
Gregory M Glenn, Carl R Alving: Adjuvant for transcutaneous immunization. The United States of America represented by the U S Army Medical Research & Material Command, Pillsbury Madison & Sutro, November 9, 1999: US05980898 (27 worldwide citation)

A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and/or cellu ...


9
Carl R Alving, Edgar A Steck: Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates. The United States of America represented by the Secretary of the Army, William G Gapcynski, Arthur I Spechler, Werten F W Bellamy, November 22, 1983: US04416872 (27 worldwide citation)

A novel treatment has been discovered for interrupting the life cycle of malaria parasite during its development in the liver of the vertebrate host. The subject invention involves a method of chemotherapy against sporozoite-induced malaria by administering an 8-aminoquinoline drug, such as primaqui ...


10
Carl R Alving, Roberta R Owens, Nabila M Wassef: Process for making liposome preparation. The United States of America represented by the Secretary of the Army, Charles H Harris, John Francis Moran, December 28, 1999: US06007838 (20 worldwide citation)

A process for making a liposome preparation comprised of liposomes that contain an encapsulated material is disclosed. The process comprises (A) providing a plurality of portions of a lipid or liposome formulation; (B) hydrating each of the plurality of portions with a solution comprising a material ...